Skip to Content

Rhythm Pharmaceuticals Inc RYTM

Morningstar Rating
$39.71 −0.29 (0.73%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RYTM is trading at a 7% premium.
Price
$40.02
Fair Value
$78.38
Uncertainty
Very High
1-Star Price
$39.43
5-Star Price
$65.39
Economic Moat
Tkfv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RYTM is a good fit for your portfolio.

Trading Information

Previous Close Price
$40.00
Day Range
$39.5640.99
52-Week Range
$15.5052.57
Bid/Ask
$38.01 / $50.00
Market Cap
$2.39 Bil
Volume/Avg
398,307 / 581,504

Key Statistics

Price/Earnings (Normalized)
Price/Sales
29.58
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
226

Comparables

Valuation

Metric
RYTM
KROS
CBAY
Price/Earnings (Normalized)
Price/Book Value
13.905.3912.65
Price/Sales
29.58111.01
Price/Cash Flow
Price/Earnings
RYTM
KROS
CBAY

Financial Strength

Metric
RYTM
KROS
CBAY
Quick Ratio
5.2713.6310.70
Current Ratio
5.5814.2510.96
Interest Coverage
−13.26−5.27
Quick Ratio
RYTM
KROS
CBAY

Profitability

Metric
RYTM
KROS
CBAY
Return on Assets (Normalized)
−46.12%−35.62%−30.06%
Return on Equity (Normalized)
−76.97%−39.15%−51.97%
Return on Invested Capital (Normalized)
−76.40%−41.95%−30.87%
Return on Assets
RYTM
KROS
CBAY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXgdqmswcgRmh$562.4 Bil
VRTX
Vertex Pharmaceuticals IncTzkzqdcNnnwgw$103.6 Bil
REGN
Regeneron Pharmaceuticals IncGfnrxblkQzjkvy$99.5 Bil
MRNA
Moderna IncBhfnbjjnzPkqp$38.8 Bil
ARGX
argenx SE ADRMmdkfprhmCxf$22.3 Bil
BNTX
BioNTech SE ADRWtqywjgYpwx$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncWhgkdkkBrglcj$18.2 Bil
BMRN
Biomarin Pharmaceutical IncBjfpllgzYrzzdrl$17.3 Bil
RPRX
Royalty Pharma PLC Class AMjcbtkbzNwqskg$12.5 Bil
INCY
Incyte CorpRjkdnlxsWyhqxv$11.6 Bil

Sponsor Center